Systemic Eczema Therapy: Dupilumab and the Type-2 Revolution

When the topical ladder runs out

Systemic therapy is not the next rung — it is a different staircase. The Atopic Dermatitis chapter laid out the topical ladder: emollients as the foundation, topical corticosteroids by potency, and the calcineurin inhibitors (tacrolimus, pimecrolimus) for delicate sites. That ladder controls most disease. But when eczema is moderate-to-severe and stays uncontrolled despite correct, well-applied topical therapy — or when the surface area is simply too large for creams to be practical — the question changes from "which cream?" to "how do I quiet the immune signal driving this from the inside?" That is the province of systemic therapy. To use it well you first have to understand the specific inflammation you are trying to switch off.

The type-2 axis: the engine of atopic disease

Atopic dermatitis is not random inflammation — it is a specific immune program running too hot. When the skin barrier is breached, dendritic cells present allergens to naïve T cells and push them down one particular path — into T-helper-2 (Th2) cells. These Th2 cells pour out a signature set of cytokines, and two of them, interleukin-4 (IL-4) and interleukin-13 (IL-13), are the twin engines of the whole disease. IL-4 and IL-13 do three destructive things at once. First, they sabotage the skin barrier: they suppress the structural proteins (filaggrin, loricrin) and the lipids that hold the outer layer watertight, so the barrier leaks and lets more allergen in — a self-feeding loop. Second, they drive B cells to class-switch and manufacture immunoglobulin E (IgE), the antibody of allergy. Third — and this is what patients feel — they sensitise the itch nerves directly. On top of this the Th2 program releases interleukin-31 (IL-31), a cytokine whose near-sole job is to scream "itch" to the sensory nerves in the skin. Understand these four players — IL-4, IL-13, IL-31, IgE — and every modern eczema drug falls into place, because each one is aimed at a specific node on this axis.

Dupilumab: the landmark biologic

One antibody, both foremen silenced. Dupilumab is a monoclonal antibody against IL-4Rα, the receptor subunit that IL-4 and IL-13 share. Because it blocks the common docking point, a single drug shuts down the signalling of both master cytokines at once — that is the whole reason it works so broadly. Clinically it does exactly what the biology predicts: it heals the barrier, calms the redness, and — most valued by patients — it takes the itch down, often before the visible skin has fully cleared. It was the first biologic licensed for atopic dermatitis and it reset expectations for the whole field. Its safety profile is a large part of its appeal: because it targets one narrow immune axis rather than suppressing immunity broadly, there is no routine blood monitoring required — a striking contrast to every older systemic. Its signature adverse effect is conjunctivitis: a proportion of patients develop red, gritty, inflamed eyes, a class quirk of IL-4Rα blockade that is usually manageable with lubricants or topical treatment and rarely forces the drug to be stopped. Injection-site reactions and, less commonly, a facial/head-and-neck redness are also seen. It is given by subcutaneous injection, is safe enough for long-term use, and can be used in children.

The rest of the biologic bench: IL-13 and IL-31

If IL-4 and IL-13 are the twin engines, some drugs choose to block just one of them. Tralokinumab and lebrikizumab are monoclonal antibodies against IL-13 alone. The rationale is that IL-13 may be the more dominant driver in the skin itself, so neutralising it specifically can control disease while sparing IL-4's other roles. In practice they are effective systemic options with a similarly clean, monitoring-light profile, and they broaden the biologic menu for patients who do not respond to or tolerate dupilumab. Then there is a drug aimed squarely at the symptom rather than the disease: nemolizumab, a monoclonal antibody against the IL-31 receptor. Because IL-31 is the dedicated itch cytokine, blocking its receptor produces a rapid, powerful reduction in itch — particularly useful in the itch-dominant phenotype and in the intensely pruritic condition prurigo nodularis. It is a reminder that in atopic disease, controlling the itch is not a cosmetic goal; the scratch-itch cycle is part of what drives the inflammation.

Oral JAK inhibitors: speed and potency, with strings attached

If biologics silence the messenger, JAK inhibitors jam the receiver inside the cell. A biologic mops up a cytokine outside the cell. A JAK inhibitor works from within. When a type-2 cytokine binds its receptor, the signal is carried inward by a relay of enzymes called Janus kinases (JAK1, JAK2, JAK3, TYK2) that in turn switch on STAT proteins — the JAK-STAT pathway. Many of the type-2 cytokines, including IL-4 and IL-13, funnel their signal through this pathway. An oral small molecule that blocks JAK1 therefore chokes off the intracellular message from several itch- and inflammation-driving cytokines at once. The clinical payoff is speed and potency: abrocitinib and upadacitinib (and, more modestly, baricitinib) can cut the itch within days and clear skin fast — often faster than a biologic. They are tablets, not injections, which some patients much prefer, and they are easy to start and stop, with the effect wearing off quickly once discontinued (their reversibility). This same JAK-STAT machinery is the shared engine behind the topical JAK inhibitors and the systemic JAK drugs used in Psoriasis (where the TYK2 inhibitor deucravacitinib features), so the pathway is worth learning once and reusing across chapters.

The catch is a class-wide boxed warning. The reach of JAK inhibition is also its danger: JAK-STAT signalling is used by many immune and haematopoietic cells, so blocking it broadly carries risks that biologics largely avoid. The whole oral JAK class carries a boxed warning — extrapolated in part from a large rheumatoid-arthritis safety study of an earlier JAK drug — flagging venous thromboembolism (VTE, i.e. clots), major adverse cardiovascular events (MACE), malignancy, serious infections, and reactivation of herpes zoster (shingles). This is not a reason never to use them; it is the reason they demand patient selection and monitoring. Before starting, you screen for latent infections (tuberculosis, hepatitis B and C) and assess cardiovascular and thrombotic risk, and consider zoster vaccination. During treatment you monitor blood counts (they can drop neutrophils, lymphocytes, platelets and haemoglobin) and lipids (they can raise cholesterol), and stay alert for infection. So the JAK inhibitors invert dupilumab's bargain: you buy greater speed and oral convenience at the cost of a real monitoring burden and a serious risk profile.

The old guard: non-selective systemics

Before the targeted era, severe eczema was controlled with immunosuppressants borrowed from transplant medicine and rheumatology — the same agents taught in the Inflammation section. Ciclosporin, a calcineurin inhibitor, works fast and is genuinely effective, but it is a short-term rescue drug: prolonged use damages the kidneys and drives up blood pressure, so it is used to break a severe flare, not to maintain control for years. Methotrexate (an antifolate that dampens rapidly dividing immune cells) and azathioprine (a purine antimetabolite) are slower-onset options for longer-term control, each demanding regular blood monitoring for marrow suppression and liver toxicity — and azathioprine's tolerance depends on the patient's TPMT enzyme activity, which is checked before starting. Mycophenolate mofetil is another antiproliferative sometimes used off-label. And systemic corticosteroids? They work dramatically and quickly — which is exactly the trap. In atopic dermatitis they are, at most, a very short rescue for a crisis, because stopping them reliably triggers a fierce rebound flare, often worse than the original, and because their long-term toxicities are unacceptable for a lifelong disease. Reaching repeatedly for oral steroids in eczema is one of the classic management errors.

Choosing: biologic or JAK?

Once you have decided a patient needs systemic therapy, the modern decision is usually between a biologic (dupilumab and its cousins) and an oral JAK inhibitor — and the two make opposite bargains. Favour a biologic when safety and simplicity lead: it has a clean profile, needs no routine bloods, and is the natural first choice in patients with cardiovascular or thrombotic risk factors, a history of malignancy, or where a long, low-maintenance course is the goal — the cost being slower onset and an injection. Favour a JAK inhibitor when speed and route matter most: it can rescue an intensely itchy patient within days, is oral, and is easily reversible for someone who wants an on/off option — the cost being the boxed-warning risk profile and a real screening-and-monitoring burden, which makes it less suitable in the older or comorbid patient. Comorbidity is often the deciding vote: a young patient drowning in itch who wants tablets and fast relief tilts toward a JAK; an older patient with cardiovascular risk tilts firmly toward a biologic. And this is not a one-way door — patients who fail or cannot tolerate one class frequently switch to the other. The type-2 axis has, at last, given dermatology a real menu.